Our recent study has shown that administration of PPARγ agonists, rosiglitazone and pioglitazone decreases the IL-17 protein and mRNA expression in the lung and reduces Th2 cytokine expression, AHR, and eosinophil activation, which are increased by induction of asthma [68]. The gene discussed is AHR; the disease is asthma.